Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of APX001 (PF-7842805) in Invasive Mold Infections
2019-001386-33Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jul 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fosmanogepix in Invasive Mold Infections (IMIs), invasive mycoses, aspergillosis and 3 more, sponsored by Pfizer. Primary endpoint: All-cause mortality through Day 42. Started Jul 2019; status: terminated.
02
Drugs
fosmanogepix
03
Conditions
Invasive Mold Infections (IMIs)invasive mycosesaspergillosisallescheriosisfusariosis
Beyond the preview
Go deeper on 2019-001386-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001386-33.